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Abstract
Background: Although lateral internal sphincterotomy is the gold-standard treatment for chronic
anal fissure, intrasphincteric injection of botulinum toxin seems to be a reliable new option. The
aim of this non-randomized study is to compare the effect of lateral internal sphincterotomy and
botulinum toxin injection treatments on the outcome and reduction of anal sphincter pressures in
patients with chronic anal fissure.
Methods: Patients with chronic anal fissure were treated with either botulinum toxin injection or
lateral internal sphincterotomy by their own choice. Maximal resting pressure and maximal squeeze
pressure measurements were performed before and 2 weeks after treatments by anal manometry.
Patients were followed for fissure relapse during 14 months.
Results: Twenty-one consecutive outpatients with posterior chronic anal fissure were enrolled.
Eleven patients underwent surgery and ten patients received botulinum toxin injection treatment.
Before the treatment, anal pressures were found to be similar in both groups. After the treatment,
the maximal resting pressures were reduced from 104 ± 22 mmHg to 86 ± 15 mmHg in the surgery
group (p < 0.05) and from 101 ± 23 mmHg to 83 ± 24 mmHg in the botulinum toxin group (p <
0.05). The mean maximal squeeze pressures were reduced from 70 ± 27 mmHg to 61 ± 32 mmHg
(p > 0.05) in the surgery group, and from 117 ± 62 mmHg to 76 ± 34 (p < 0.01) in the botulinum
toxin group. The fissures were healed in 70 percent of patients in the botulinum group and 82
percent in the surgery group (p > 0.05). There were no relapses during the 14 months of follow up.
Conclusion: Lateral internal sphincterotomy and botulinum toxin injection treatments both seem
to be equally effective in the treatment of chronic anal fissure.
Background
Increases in resting anal pressure are documented in
patients with chronic anal fissures (CAF) and it has been
considered as a major pathophysiologic factor. Therapies
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achieve fissure healing. Lateral internal sphincterotomy
(LIS) is the most common treatment for CAF [1] and can
be effective in more than 90 percent of cases but needs
general or local anesthesia [2]. The fundamental draw-
back of this surgery is its potential to cause gas, mucus or
occasionally stool incontinence which is permanent in 8
to 30 percent of patients and may be associated with
abscess and anal deformity [3-8].
Intrasphincteric injection of botulinum toxin (BT) is a
reliable and effective new option in the treatment of
uncomplicated CAF. This method has been described ini-
tially by Jost and Schmrigk [9], and was found to be an
effective treatment in comparison with placebo [10]. Fur-
thermore, BT was more effective than topical nitrate,
which constitutes another therapeutic option [11], and no
permanent damage to the continence mechanism was
detected in patients treated with BT [10,12,13]. The aim of
this non-randomized, prospective and controlled study
was to compare the therapeutic efficacy of BT injection




Consecutive adults with symptomatic CAF were enrolled
into the study. The diagnosis of CAF was based on the fol-
lowing criteria: evidence of posterior circumscribed ulcer,
with a large sentinel tag of skin, induration at the edges,
and exposure of the horizontal fibers of the internal anal
sphincter (IAS); symptoms (post-defecatory or nocturnal
pain, bleeding, or both) lasting for more than two
months. Criteria for exclusion from the study were com-
plicated fissure and important secondary changes, i.e., cic-
atricial deformation, large sentinel pile and subfissural
infiltration. Patients were fully informed about the effect
and possible side effects of LIS and BT injection. This
study was approved by the institutional review board of
PTT Hospital.
Study design
This study was designed in a non-randomized fashion.
Treatment arms were decided according to the patients'
will. All the patients underwent a pre-treatment evalua-
tion which included clinical inspection of the fissure and
anorectal manometry.
Anal manometry
Anal sphincter manometry was performed on the CAF
patients before and at the 3rd week of the treatment. Man-
ometry was carried out by a pre-calibrated, water per-
fusion system using a catheter with 8 holes 0.5 cm apart
(Andorfer Inc. Wisconsin, USA). Manometric data was
stored and analyzed with computer software (Smartgraph
Rev.3.40, Sandhill Scientific Inc., Highlands Ranch, Colo-
rado, USA). Anal digital examination was not performed
before manometry to avoid the effects of anal dilatation
on sphincter pressures. All patients were studied after a
bowel preparation with enema (Fleet Enema, C.B. Fleet
Co. Inc. USA). Patients were placed comfortably in the left
lateral position. After the insertion of the catheter into the
rectum, maximal resting pressure (MRP) and maximal
squeeze pressure (MSP) measurements were done. MRP
was defined as the average of maximal pressures obtained
from all holes by stationary pull-through technique. MSP
was defined as the mean of differences between the mean
pressures obtained by voluntary squeezing for 5 seconds
and resting pressures when all of the holes were within the
anal canal. Patients were instructed to squeeze their anus
as much as they could without squeezing their abdominal
and buttock muscles throughout the entire period of MSP
measurement in order to record actual sphincter pressures
and to prevent pressure interactions.
Lateral internal sphincterotomy
LIS was performed under general or spinal anesthesia in
the lithotomy position by a technique through a circum-
ferential incision placed laterally to the skin outside the
anal verge. The anoderm and inter sphinteric grove were
dissected, and then the sphincter was divided under direct
vision. The wound was either left open or was closed with
interrupted sutures.
Botulinum-toxin injection
Botulinum toxin (Botox, Allergan, Ireland) was diluted
with saline to 40 U/ml and 10 U was injected on both
sides of the fissure (total dose 20 U and volume 0.5 ml)
by a so-called insulin syringe with a short, thin needle (10
mm, 26 gauge needle, 1 mL, Hayat, Turkey). After injec-
tion, conservative measures, such as sitting baths and/or
anal tampons for the period of healing (at least for the
first weeks) were recommended.
The primary end points of the study were complete heal-
ing of the CAF and complications after treatment. The
treatment was considered successful if the fissure healed
with a scar two months after the treatment (evaluation for
treatment efficacy). Unhealed fissures were considered as
treatment failure and dropped from follow up. Complica-
tions were described as incontinence (soiling, flatus and
feces), abscess and thrombosed hemorrhoids. The sec-
ondary end point of the study was relapse of the fissures.
The patients with healed fissures were followed clinically
for at least 12 months. In the follow up period, patients
were re-examined by inspection and re-evaluated for
symptoms at 6th and 12th months (evaluation for fissure
relapse).Page 2 of 6
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The results are expressed as mean ± SD. Manometric data
were compared between the groups by using Student t-test
and Mann-Whitney test according to the differences
between SDs of the data. Differences in percentages were
analyzed with use of Fisher's exact test. Probability values
of less than 0.05 were considered significant.
Results
Twenty-one consecutive outpatients with posterior CAF
were enrolled. Eleven patients underwent LIS and ten
patients underwent BT. The two groups were similar with
regards to age, sex, duration of symptoms, MRP and MSP
(Table 1). There were no complications during or after BT
injection.
The MRP (104 ± 22 mmHg and 101 ± 23 mmHg for LIS
and BT injection group respectively, p > 0.05) and the
MSP (70 ± 27 mmHg and 117 ± 62 mmHg for LIS and BT
injection group respectively, p > 0.05) were found to be
similar between LIS and BT group before treatment. After
treatment, the MRP was reduced to 86 ± 15 mmHg in the
LIS (p < 0.05) and to 83 ± 24 mmHg in the BT group (p <
0.05). MSP was reduced to 61 ± 32 (p > 0.05) in the LIS
group and to 76 ± 34 (p < 0.01) in the BT group (Table 2).
Inspection at 2 months after treatment revealed a healing
scar in 7 (70 percent) patients in the BT group and 9 (82
percent) in the LIS group (p > 0.05). Two of three patients
whose fissures were not healed with BT injection under-
went LIS at 1 and 2 months after BT treatment. The other
patients had an asymptomatic fissure and refused surgical
treatment. All of the patients who had an unhealed fissure
at 2 months after treatment were dropped from the follow
up in this study.
No fissure relapse was observed at the 6th and 12th month
during follow up period in the two treatment groups. The
patients in the botulinum toxin injection group and LIS
group were followed for mean of 14 ± 1 months and 14 ±
1 months respectively. There were no relapses, complica-
tions, or side effects during this follow up period.
Discussion
We have shown that LIS and BT injection treatment
modalities have had similar effects on internal anal
sphincter pressures, have similar fissure healing rates and
no recurrence in long-term follow-up. We can suggest that
LIS and BT injection treatment are equally effective in the
treatment of CAF patients.
Increase in resting anal pressure is documented in patients
with chronic anal fissure, which exceeds 30 mm Hg or
more when compared with healthy controls and is associ-
ated with a decrease in posterior anal blood flow [14,15].
Any prolonged increases in pressure may cause ischemic
damage by decreasing blood flow to the sphincter muscle
and overlying epithelium [14]. As a consequence, thera-
pies that reduce IAS pressure have been used for fissure
healing. Many chronic fissures do not heal with aggressive
Table 1: Clinical characteristics of both groups on entry into the study.
Baseline characteristics BT (n = 10) LIS (n = 11)
Age (years) 41 ± 11 39 ± 10
Sex (female/male) 4/6 7/4
Symptom duration (months) 10 ± 6 11 ± 6
Maximal Resting Pressure (mmHg) 101 ± 23 104 ± 22
Maximal Squeeze Pressure (mmHg) † 70 ± 27 117 ± 62
† p > 0.05 for the comparison between the two groups (by Mann-Whitney test).
Table 2: Comparisons of anal pressures before and after assigned treatment.
Maximal resting pressure (mmHg) Maximal squeeze pressure (mmHg)
Groups Before treatment After treatment P Before treatment After treatment P
BT 101 ± 23 83 ± 24 <0.05 117 ± 62 76 ± 34 <0.01
LIS 104 ± 22 86 ± 15 <0.05 70 ± 27 61 ± 32 >0.05
BT = Botulinum toxin injection. LIS = Lateral internal sphincterotomy. p > 0.05 for the comparisons between the two groups (BT vs. LIS).Page 3 of 6
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omy. Although surgery is effective, fissure healing and
relapse rates are quite variable. After lateral sphincterot-
omy the healing rates range from >90 percent [16] to 78
percent [17], and the recurrence rates range between 1.3
and 13.1 percent [2,7,18]. These variations could be due
to the type of surgical technique (open vs. subcutaneous
sphincterotomy) or the length of the sphincterotomy inci-
sion. Fissure healing rate is relatively low (82 percent)
after LIS procedure in this study, which may be related to
a more conservative approach in sphincterotomy in order
to prevent anal incontinence. Neither significant inconti-
nence nor relapse was observed during 14 months follow-
up period.
Botulinum toxin injection into anal sphincter is another
therapeutic approach which have been used to treat
chronic anal fissure and avoid the risk of permanent
injury to the anal sphincter [9,10,13]. Although chemical
denervations with botulinum toxin have been mostly
used for weakening of striated muscles, it has also been
found to weaken smooth muscle in the gastrointestinal
tract [19,20]. The toxin acts rapidly and prevents the
release of acetylcholine by presynaptic nerve terminals.
Paralysis occurs within a few hours, and the transmission
of neuromuscular impulses resumes after the growth of
new axon terminals [19,21]. On the third day after the
injection, the EAS tone was obviously reduced [9]. Chem-
ical denervation produced by the toxin is not permanent
and the clinical efficacy lasts for 2–3 months [18]. In anal
fissure, however, the duration of action of the toxin
roughly corresponds to the time required to reduce the
resting pressure of the anal sphincter and allows enough
time for healing.
In the present study the healing rate of 70% in the BT
group is similar to that in previous studies [9,10,12,13].
We observed significant decrease in both IAS and EAS but
interestingly, Gui et al. [13] and Maria et al. [10] did not
observe any effect of BT on EAS after injection to IAS. They
concluded that toxin injected to the IAS had not spread
into EAS [11]. This suggestion may not be valid and could
be related with type II error bias. We think that after the
injection into IAS, spread of the toxin through the EAS is
possibly due to the small thickness of IAS and the proxim-
ity of EAS to the IAS. It is also well known that a diffusion
gradient crossing even the bone and fascia spreads to a
distance of 30–45 mm from the injection point [22]. The
other reason of this controversy between our results and
the others' may also be related to the volume of the toxin.
We used a higher volume (0.5 mL) than Maria et al (0.4
mL) and this might have diffused beyond the target mus-
cle and might have weakened the adjacent muscles
[22,23]. The change in resting pressure was not men-
tioned by Jost and Schimrigk in their initial studies where
they injected BT into the EAS [9,12]. In this study, we did
not try to inject BT specifically into the IAS or EAS. We also
observed that if the toxin was applied on both sides of the
fissure it spread into the EAS and IAS, and we believe it is
easier to inject the toxin in this manner. In conclusion, the
target muscle for injection of BT seems to be irrelevant.
After therapy with BT, higher recurrence rates are
expected, because the sphincter tone is only temporarily
reduced. However, we and others have shown that relapse
rates after BT injection was very low [10-13]. Recently,
posteriorly localized fissures, significant reduction in
maximum squeeze pressure and short duration of symp-
toms (<12 months) were suggested as predictive factors
for a favorable outcome in botulinum toxin treatment in
CAF [24]. All of our patients had posterior anal fissure and
short symptom duration (mean 10 months), and signifi-
cant reduction of maximally squeeze pressure (-34%) was
achieved in the botulinum toxin group. These positive
predictive factors could be related with the good outcome
of our patients treated with BT.
Theoretically BT injection can produce anal incontinence.
BT produces a significant and global reduction in mean
resting pressure of the anal canal, but also induces a sig-
nificant increase in manometric asymmetry of the anal
canal [19]. However, incontinence has been a negligible
complication of BT treatment. EAS is an important com-
ponent of continence. Toxin injection produces sufficient
weakness of this muscle, but does not completely block
voluntary control which is enough for incontinence pre-
vention [25].
The therapeutic success rate of BT seems to be related with
injection site and toxin dose. We injected the BT on each
site of the fissure, mainly to the posterior of the anal
sphincter. However it was suggested that anterior injec-
tion of BT could better reduce the resting pressure of the
anal sphincter (88 percent vs. 60 percent) which could be
due to the fibrotic base of the fissure or ischemic degener-
ation of the myenteric plexus of posterior sphincter [26].
In addition the dose of BT is important. We used 20 units
in this study. However, it was suggested that higher doses
(up to 50 units) provide a higher success rate (up to 96
percent), without a significant rise in complications or
side effects [27].
In a recent randomized, prospective study comparing BT
with LIS for CAF, it has been suggested that the healing
effect of BT appears slowly and wanes with longer follow-
up, whereas LIS provides a faster, more stable and perma-
nent effect [28]. The success rate of the BT group fell to
75.4 percent, whereas it remained stable in the LIS group
(94 percent) at 12 months. In conclusion, the authors sug-
gested that BT injection is inferior to LIS in the treatmentPage 4 of 6
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incontinence of varying degrees after surgery, compared
with a 0 prevalence in the BT group (p < 0.001) within the
same follow-up period. If anal incontinence is considered
as a failure of LIS, the advantage of this treatment will dis-
appear [29].
In conclusion, BT injection is effective in the treatment of
CAF. It is relatively less invasive than surgery and the com-
plication rate seems negligible. However BT injection
treatment may provide temporary remissions. Larger
scale, randomized controlled studies with long term fol-
low up are needed before making firm conclusions about
the advantages of this treatment modality over the con-
ventional methods.
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